PharmaResearch Co., Ltd. (214450.KQ)
KRW 259500.0
(2.77%)
KRW 259500.0
(2.77%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 76.55 Billion KRW | 88.66% |
| 2022 | 40.57 Billion KRW | -13.09% |
| 2021 | 46.68 Billion KRW | 42.45% |
| 2020 | 32.77 Billion KRW | 96.64% |
| 2019 | 16.66 Billion KRW | 15.68% |
| 2018 | 14.4 Billion KRW | 11.21% |
| 2017 | 12.95 Billion KRW | -6.86% |
| 2016 | 13.9 Billion KRW | 8.01% |
| 2015 | 12.87 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 31.38 Billion KRW | 82.0% |
| 2024 Q1 | 17.24 Billion KRW | 11.93% |
| 2023 Q4 | 15.4 Billion KRW | -42.32% |
| 2023 Q2 | 16.73 Billion KRW | -5.49% |
| 2023 Q1 | 17.7 Billion KRW | 371.17% |
| 2023 Q3 | 26.7 Billion KRW | 59.63% |
| 2023 FY | 76.55 Billion KRW | 88.66% |
| 2022 Q1 | 9.31 Billion KRW | -3.78% |
| 2022 FY | 40.57 Billion KRW | -13.09% |
| 2022 Q4 | 3.75 Billion KRW | -78.43% |
| 2022 Q2 | 10.08 Billion KRW | 8.21% |
| 2022 Q3 | 17.42 Billion KRW | 72.82% |
| 2021 Q1 | 12.25 Billion KRW | 21.29% |
| 2021 Q2 | 11.46 Billion KRW | -6.42% |
| 2021 Q3 | 13.28 Billion KRW | 15.88% |
| 2021 Q4 | 9.68 Billion KRW | -27.14% |
| 2021 FY | 46.68 Billion KRW | 42.45% |
| 2020 Q2 | 10.08 Billion KRW | 106.91% |
| 2020 Q3 | 7.71 Billion KRW | -23.54% |
| 2020 Q4 | 10.1 Billion KRW | 31.01% |
| 2020 FY | 32.77 Billion KRW | 96.64% |
| 2020 Q1 | 4.87 Billion KRW | 12.55% |
| 2019 Q2 | 3.38 Billion KRW | -34.08% |
| 2019 FY | 16.66 Billion KRW | 15.68% |
| 2019 Q4 | 4.33 Billion KRW | 13.46% |
| 2019 Q3 | 3.81 Billion KRW | 12.77% |
| 2019 Q1 | 5.13 Billion KRW | -23.63% |
| 2018 FY | 14.4 Billion KRW | 11.21% |
| 2018 Q4 | 6.72 Billion KRW | 489.44% |
| 2018 Q3 | 1.14 Billion KRW | -50.65% |
| 2018 Q1 | 4.23 Billion KRW | 648.65% |
| 2018 Q2 | 2.31 Billion KRW | -45.39% |
| 2017 Q3 | 5.36 Billion KRW | 42.76% |
| 2017 Q2 | 3.75 Billion KRW | -18.52% |
| 2017 Q1 | 4.6 Billion KRW | 479.67% |
| 2017 FY | 12.95 Billion KRW | -6.86% |
| 2017 Q4 | -771.45 Million KRW | -114.39% |
| 2016 Q4 | 795.2 Million KRW | -81.56% |
| 2016 Q1 | 4.14 Billion KRW | 14.69% |
| 2016 FY | 13.9 Billion KRW | 8.01% |
| 2016 Q3 | 4.31 Billion KRW | -7.48% |
| 2016 Q2 | 4.66 Billion KRW | 12.55% |
| 2015 FY | 12.87 Billion KRW | 0.0% |
| 2015 Q4 | 3.61 Billion KRW | -8.87% |
| 2015 Q3 | 3.96 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| HLB Co., Ltd. | -189.07 Billion KRW | 140.486% |
| iNtRON Biotechnology, Inc. | -9.69 Billion KRW | 889.561% |
| BINEX Co., Ltd. | 4.67 Billion KRW | -1538.95% |
| Bioneer Corporation | -10.58 Billion KRW | 823.066% |
| Anterogen.Co.,Ltd. | -2.84 Billion KRW | 2794.659% |
| MEDIPOST Co., Ltd. | 5.83 Billion KRW | -1210.809% |
| CrystalGenomics, Inc. | -48.92 Billion KRW | 256.471% |
| Helixmith Co., Ltd | -64.08 Billion KRW | 219.446% |
| Chabiotech Co.,Ltd. | -8.43 Billion KRW | 1007.946% |
| Medy-Tox Inc. | 9.75 Billion KRW | -684.73% |
| Peptron, Inc. | -15.92 Billion KRW | 580.792% |
| Amicogen, Inc. | -23.28 Billion KRW | 428.702% |
| Genexine, Inc. | -66.87 Billion KRW | 214.472% |
| HLB Therapeutics Co.,Ltd. | -2.3 Billion KRW | 3425.193% |
| LegoChem Biosciences, Inc. | -73.7 Billion KRW | 203.864% |
| ALTEOGEN Inc. | -3.37 Billion KRW | 2370.361% |
| SillaJen, Inc. | -20.36 Billion KRW | 475.818% |
| JETEMA, Co., Ltd. | 13.96 Billion KRW | -448.129% |
| OliX Pharmaceuticals,Inc | -19.1 Billion KRW | 500.756% |
| Genomictree Inc. | -8.75 Billion KRW | 974.268% |
| MedPacto, Inc. | -35.32 Billion KRW | 316.707% |
| D&D Pharmatech | 3.93 Billion KRW | -1845.984% |
| EASY BIO,Inc. | 15.54 Billion KRW | -392.488% |
| GI Innovation, Inc. | -55.49 Billion KRW | 237.942% |